Business Context and Reporting Period
Company: Relmada Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 15, 2021
Reporting Period: Specific event date of March 15, 2021.
Business Context: The registrant is a clinical-stage biopharmaceutical company focused on developing REL-1017 (esmethadone). This filing discloses the completion of preclinical abuse studies as part of an ongoing abuse assessment program.
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
Event: Completion of preclinical abuse studies on REL-1017 (esmethadone).
Details: The company released conclusions from these studies on March 15, 2021. Full abstracts are scheduled for presentation at upcoming scientific conferences. The conclusions are attached as Exhibit 99.1.
Guidance, Outlook, and Risks
Outlook: The company intends to present full abstracts of the study conclusions at upcoming scientific conferences.
Risks and Forward-Looking Statements: The filing contains forward-looking statements regarding operating results and future prospects. These statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results. Investors are cautioned not to rely unduly on these statements.
Regulatory Note: The information in Item 7.01 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific conclusions of the preclinical abuse studies on REL-1017.
- Monitor upcoming scientific conferences for the presentation of full abstracts regarding these studies.
- Verify the status of the ongoing abuse assessment program for REL-1017 in subsequent filings.
- Consult the company's most recent 10-K or 10-Q for financial position and liquidity data, as this 8-K does not contain such information.